KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Non-Current Deferred Tax Liability (2018 - 2025)

Historic Non-Current Deferred Tax Liability for Emergent BioSolutions (EBS) over the last 10 years, with Q3 2025 value amounting to $36.3 million.

  • Emergent BioSolutions' Non-Current Deferred Tax Liability fell 1336.52% to $36.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.3 million, marking a year-over-year decrease of 1336.52%. This contributed to the annual value of $41.7 million for FY2024, which is 2920.2% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Non-Current Deferred Tax Liability of $36.3 million as of Q3 2025, which was down 1336.52% from $46.5 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Non-Current Deferred Tax Liability registered a high of $130.7 million during Q4 2021, and its lowest value of $34.8 million during Q1 2024.
  • Its 5-year average for Non-Current Deferred Tax Liability is $65.4 million, with a median of $53.3 million in 2021.
  • As far as peak fluctuations go, Emergent BioSolutions' Non-Current Deferred Tax Liability surged by 11490.57% in 2022, and later tumbled by 5399.47% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Non-Current Deferred Tax Liability (Quarter) stood at $130.7 million in 2021, then decreased by 4.06% to $125.4 million in 2022, then crashed by 53.03% to $58.9 million in 2023, then fell by 29.2% to $41.7 million in 2024, then decreased by 12.95% to $36.3 million in 2025.
  • Its Non-Current Deferred Tax Liability was $36.3 million in Q3 2025, compared to $46.5 million in Q2 2025 and $60.4 million in Q1 2025.